Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.  Pluristem’s core technology is placenta-derived cells that are being developed as a real ‘off-the-shelf’ therapeutic product for critical high unmet need indications, where there are limited or no alternative treatment options available. For example, Pluristem’s lead product, PLX PAD is in clinical development for diseases such as critical limb ischemia (CLI) and hip fractures.

In major news released today, Pluristem announced that it entered into a licensing agreement with TES Holdings Co., Ltd. to obtain a key patent in Japan that will cover the treatment of ischemic diseases with placental cell therapy. This is a significant announcement, as the company released news last week that it had been granted two key cell therapy patents in Japan.

To learn more, see the full press release issued by Pluristem below or read our recent interview with Dr. Racheli Ofir, VP Research & Intellectual Property at Pluristem Therapeutics.

Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke

Press Release; Haifa, Israel, April 21, 2016 — Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PLTR), a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic diseases with placental cell therapy rounding out the Company’s IP coverage. This license follows Pluristem’s recent announcement that the Japan Patent Office granted the Company two key patents addressing three-dimensional methods for expanding placental and adipose cells, and specified cell therapies produced from placental tissue using these methods. [Read more…]